title: Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.
abstract: The Wilms' tumor gene WT1 is a reliable marker for minimal residual disease assessment in acute leukemia patients. The study was designed to demonstrate the potential use of WT1 to establish quality of remission in acute leukemia patients for early identification of patients at high risk of relapse. A prospective study based on a quantitative Real-Time PCR (TaqMan) assay in 562 peripheral blood samples collected from 82 acute leukemia patients at diagnosis and during follow-up was established. The evaluation of WT1 in peripheral blood samples after induction chemotherapy can distinguish the continuous complete remission patients from those who obtain only an "apparent" complete remission and who could relapse within a few months. WT1 helps identify patients at high risk of relapse soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified.
authors.affiliation: Dept. of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano, Turin, Italy. daniela.cilloni@unito.it
authors.forename: Daniela
authors.initials: D
authors.lastname: Cilloni
authors.forename: Francesca
authors.initials: F
authors.lastname: Messa
authors.forename: Francesca
authors.initials: F
authors.lastname: Arruga
authors.forename: Ilaria
authors.initials: I
authors.lastname: Defilippi
authors.forename: Enrico
authors.initials: E
authors.lastname: Gottardi
authors.forename: Milena
authors.initials: M
authors.lastname: Fava
authors.forename: Sonia
authors.initials: S
authors.lastname: Carturan
authors.forename: Renata
authors.initials: R
authors.lastname: Catalano
authors.forename: Enrico
authors.initials: E
authors.lastname: Bracco
authors.forename: Emanuela
authors.initials: E
authors.lastname: Messa
authors.forename: Paolo
authors.initials: P
authors.lastname: Nicoli
authors.forename: Daniela
authors.initials: D
authors.lastname: Diverio
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Sanz
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Lo-Coco
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D016162:Genes, Wilms Tumor; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012008:Recurrence; D012306:Risk; D016896:Treatment Outcome; D025721:WT1 Proteins / Q000097:blood* / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D025721:WT1 Proteins